Your browser doesn't support javascript.
loading
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton, Garrett M; Ali, Siraj M; Rosenzweig, Mark; Chmielecki, Juliann; Lu, Xinyuan; Bauer, Todd M; Akimov, Mikhail; Bufill, Jose A; Lee, Carrie; Jentz, David; Hoover, Rick; Ou, Sai-Hong Ignatius; Salgia, Ravi; Brennan, Tim; Chalmers, Zachary R; Jaeger, Savina; Huang, Alan; Elvin, Julia A; Erlich, Rachel; Fichtenholtz, Alex; Gowen, Kyle A; Greenbowe, Joel; Johnson, Adrienne; Khaira, Depinder; McMahon, Caitlin; Sanford, Eric M; Roels, Steven; White, Jared; Greshock, Joel; Schlegel, Robert; Lipson, Doron; Yelensky, Roman; Morosini, Deborah; Ross, Jeffrey S; Collisson, Eric; Peters, Malte; Stephens, Philip J; Miller, Vincent A.
Afiliação
  • Frampton GM; Foundation Medicine Inc., Cambridge, Massachusetts. gframpton@foundationmedicine.com.
  • Ali SM; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Rosenzweig M; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Chmielecki J; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Lu X; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.
  • Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee.
  • Akimov M; Novartis Pharma AG, Basel, Switzerland.
  • Bufill JA; Michiana Hematology-Oncology, PC, Mishawaka, Indiana.
  • Lee C; University of North Carolina School of Medicine, Clinical Research, Thoracic Oncology Program, Chapel Hill, North Carolina.
  • Jentz D; South Bend Medical Foundation, South Bend, Indiana.
  • Hoover R; South Bend Medical Foundation, South Bend, Indiana.
  • Ou SH; Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Irvine, California.
  • Salgia R; The University of Chicago School of Medicine, Chicago, Illinois.
  • Brennan T; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Chalmers ZR; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Jaeger S; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Huang A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Elvin JA; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Erlich R; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Fichtenholtz A; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Gowen KA; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Greenbowe J; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Johnson A; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Khaira D; Foundation Medicine Inc., Cambridge, Massachusetts.
  • McMahon C; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Sanford EM; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Roels S; Foundation Medicine Inc., Cambridge, Massachusetts.
  • White J; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Greshock J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Schlegel R; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Lipson D; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Yelensky R; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Morosini D; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Ross JS; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Collisson E; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.
  • Peters M; Novartis Pharma AG, Basel, Switzerland.
  • Stephens PJ; Foundation Medicine Inc., Cambridge, Massachusetts.
  • Miller VA; Foundation Medicine Inc., Cambridge, Massachusetts.
Cancer Discov ; 5(8): 850-9, 2015 Aug.
Article em En | MEDLINE | ID: mdl-25971938
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Éxons / Processamento Alternativo / Proteínas Proto-Oncogênicas c-met / Inibidores de Proteínas Quinases / Neoplasias / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Cancer Discov Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Éxons / Processamento Alternativo / Proteínas Proto-Oncogênicas c-met / Inibidores de Proteínas Quinases / Neoplasias / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Cancer Discov Ano de publicação: 2015 Tipo de documento: Article